Company profile
Moleculin Biotech, Inc.
NASDAQ:MBRXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MOL-4239 | phase2 | — | 2 | no active trials |
| WP-1122 | phase1 | — | 1 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06788756 | phase2_3 | recruiting | 2025-03-12 | 2029-08-01 | Moleculin Biotech, Inc. | L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML |
| NCT01826201 | phase2 | completed | 2013-03-01 | 2013-08-01 | Moleculin, LLC | Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis |
| NCT03315039 | phase1_2 | completed | 2018-03-28 | 2020-01-14 | Moleculin Biotech, Inc. | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) |
| NCT03388749 | phase1_2 | completed | 2018-12-17 | 2022-02-08 | Moleculin Biotech, Inc. | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) |
| NCT04887298 | phase1_2 | completed | 2021-06-05 | 2022-09-29 | Moleculin Biotech, Inc. | Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases |
FDA applications (0)
No records yet.